Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026
Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Fineline Cube Jul 2, 2026
Company Drug

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Fineline Cube Jul 2, 2026
Company

WuXi STA Breaks Ground on New US Manufacturing Site in Delaware

Fineline Cube Aug 19, 2022

WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement...

Company Deals

ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion

Fineline Cube Aug 19, 2022

China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million...

Company Drug

Zhejiang Erying’s Acetaminophen Set for CDE Priority Review in Pediatric Fever and Pain

Fineline Cube Aug 19, 2022

The Center for Drug Evaluation (CDE) has indicated that Zhejiang Erying Pharmaceutical Co., Ltd’s acetaminophen...

Company

Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing

Fineline Cube Aug 19, 2022

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in...

Company Deals

LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development

Fineline Cube Aug 19, 2022

LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...

Company Drug

Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China

Fineline Cube Aug 19, 2022

Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...

Company Deals

mProbe Raises Funds in Series B1 Round Led by AstraZeneca and CICC

Fineline Cube Aug 19, 2022

Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an...

Company Deals

Huahai Pharma to Manufacture Pfizer’s Paxlovid for China Market

Fineline Cube Aug 19, 2022

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has entered into a manufacturing and supply...

Company Drug

Recbio Completes Phase II Trial Enrollment for ReCOV COVID-19 Vaccine

Fineline Cube Aug 19, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment...

Company Deals

Healsun Biopharm Raises USD 36.7 Million in Series B Financing for Antibody CDMO Expansion

Fineline Cube Aug 19, 2022

China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization...

Company Drug

Sirnaomics Initiates Phase I/II Trial for STP705 in Facial Squamous Cell Carcinoma

Fineline Cube Aug 19, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the first subject systemic dosing in...

Policy / Regulatory

NHC, NDRC Issue Guidelines to Boost China’s Birth Rates with Reproductive Support Measures

Fineline Cube Aug 19, 2022

The National Health Commission (NHC) and National Development and Reform Commission (NDRC), along with multiple...

Company Deals

Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO

Fineline Cube Aug 19, 2022

Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...

Company Drug

CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study

Fineline Cube Aug 19, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...

Company Deals

Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech

Fineline Cube Aug 18, 2022

China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech....

Company Drug R&D

Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China

Fineline Cube Aug 18, 2022

The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...

Policy / Regulatory

CDE Releases Draft Guidelines for RWE-Backed Drug Registration Applications

Fineline Cube Aug 18, 2022

The Center for Drug Evaluation (CDE) has released a notification regarding the “Real-World Evidence (RWE)-backed...

Drug

ICT’s GCC19CART Enters US Phase I Study for Colorectal Cancer

Fineline Cube Aug 18, 2022

Sino-US firm Innovative Cellular Therapeutics (ICT) announced the involvement of the first subject in a...

Drug

BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia

Fineline Cube Aug 18, 2022

Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...

Company Legal / IP

GenScript Biotech Sues Former CSO Fan Xiaohu for Trade Secret Infringement

Fineline Cube Aug 18, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has sued its former...

Posts pagination

1 … 658 659 660 … 689

Recent updates

  • Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval
  • Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy
  • Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile
  • Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics
  • Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Company Drug

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.